Anacor Pharmaceuticals, Inc. - Press Releaseshttp://investor.anacor.com/releases.cfm?sh_auth=1288601269.0.0.15fd7bf4332ef4a945d54862439b2f0aen-usShareholder.com RSS FeedAnacor Pharmaceuticals Reports First Quarter 2013 Financial Resultshttp://investor.anacor.com/releasedetail.cfm?ReleaseID=763646Thu, 09 May 2013 20:01:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=763646Anacor Pharmaceuticals Reports First Quarter 2013 Financial ResultsAnacor Pharmaceuticals Announces First Quarter 2013 Financial Results Conference Call and Webcasthttp://investor.anacor.com/releasedetail.cfm?ReleaseID=762745Tue, 07 May 2013 20:01:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=762745Anacor Pharmaceuticals Announces First Quarter 2013 Financial Results Conference Call and WebcastAnacor Pharmaceuticals Provides Update Regarding Arbitration With Valeant Pharmaceuticalshttp://investor.anacor.com/releasedetail.cfm?ReleaseID=761684Thu, 02 May 2013 22:00:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=761684Anacor Pharmaceuticals Provides Update Regarding Arbitration With Valeant PharmaceuticalsAnacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Over-Allotment Optionhttp://investor.anacor.com/releasedetail.cfm?ReleaseID=761132Wed, 01 May 2013 21:00:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=761132Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Over-Allotment OptionAnacor Pharmaceuticals Prices $20 Million Public Offering of Common Stockhttp://investor.anacor.com/releasedetail.cfm?ReleaseID=759672Fri, 26 Apr 2013 13:00:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=759672Anacor Pharmaceuticals Prices $20 Million Public Offering of Common StockAnacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease Researchhttp://investor.anacor.com/releasedetail.cfm?ReleaseID=754908Mon, 08 Apr 2013 12:30:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=754908Anacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease ResearchAnacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitishttp://investor.anacor.com/releasedetail.cfm?ReleaseID=750026Thu, 21 Mar 2013 11:00:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=750026Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic DermatitisAnacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of Adolescents With Atopic Dermatitishttp://investor.anacor.com/releasedetail.cfm?ReleaseID=749868Wed, 20 Mar 2013 20:59:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=749868Anacor Pharmaceuticals to Hold Conference Call Tomorrow, March 21, 2013 at 8am ET / 5am PT to Discuss Preliminary Results From the Phase 2 Dose-Ranging Study of AN2728 in the Treatment of Adolescents With Atopic DermatitisAnacor Pharmaceuticals Reports 2012 Fourth Quarter and Year-End Financial Resultshttp://investor.anacor.com/releasedetail.cfm?ReleaseID=748554Thu, 14 Mar 2013 20:01:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=748554Anacor Pharmaceuticals Reports 2012 Fourth Quarter and Year-End Financial ResultsAnacor Pharmaceuticals Announces 2012 Fourth Quarter and Year End Financial Results Conference Call and Webcasthttp://investor.anacor.com/releasedetail.cfm?ReleaseID=746483Thu, 07 Mar 2013 22:00:00 GMThttp://investor.anacor.com/releasedetail.cfm?ReleaseID=746483Anacor Pharmaceuticals Announces 2012 Fourth Quarter and Year End Financial Results Conference Call and Webcast